Author

Wouter B. Nagengast

FLUORESCENCE MOLECULAR ENDOSCOPY USING CETUXIMAB-800CW TO EVALUATE THE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: PRELIMINARY RESULTS
FLUORESCENCE MOLECULAR ENDOSCOPY USING CETUXIMAB-800CW TO EVALUATE THE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: PRELIMINARY RESULTS

Wouter B. Nagengast  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)

Wouter B. Nagengast  et al.

NOVEL ULTRASOUND-GUIDED QUANTITATIVE FLUORESCENCE MOLECULAR ENDOSCOPY FOR RESPONSE MONITORING IN PATIENTS WITH ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY
NOVEL ULTRASOUND-GUIDED QUANTITATIVE FLUORESCENCE MOLECULAR ENDOSCOPY FOR RESPONSE MONITORING IN PATIENTS WITH ESOPHAGEAL CANCER AFTER NEOADJUVANT CHEMORADIOTHERAPY

Wouter B. Nagengast  et al.

RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT’S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS
RISK OF RESIDUAL CANCER AFTER ENDOSCOPIC RESECTION OF EARLY BARRETT’S NEOPLASIA WITH CONFIRMED VERTICAL R1 MARGIN: A NATIONWIDE COHORT IN THE NETHERLANDS

Wouter B. Nagengast  et al.

BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE
BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE

Wouter B. Nagengast  et al.

ENDOCYTOSCOPIC IDENTIFICATION OF DYSPLASIA IN THE BARRETT’S OESOPHAGUS USING ARTIFICIAL INTELLIGENCE AS A SECOND ASSESSOR: A PROSPECTIVE ASSESSMENT OF THE INTERACTION BETWEEN GASTROENTEROLOGISTS AND A CONVOLUTIONAL NEURAL NETWORK ALGORITHM
ENDOCYTOSCOPIC IDENTIFICATION OF DYSPLASIA IN THE BARRETT’S OESOPHAGUS USING ARTIFICIAL INTELLIGENCE AS A SECOND ASSESSOR: A PROSPECTIVE ASSESSMENT OF THE INTERACTION BETWEEN GASTROENTEROLOGISTS AND A CONVOLUTIONAL NEURAL NETWORK ALGORITHM

Wouter B. Nagengast  et al.

IDENTIFICATION AND VALIDATION OF NOVEL TARGETS FLUORESCENCE MOLECULAR ENDOSCOPY FOR NEOPLASIA DETECTION IN BARRETT’S ESOPHAGUS
IDENTIFICATION AND VALIDATION OF NOVEL TARGETS FLUORESCENCE MOLECULAR ENDOSCOPY FOR NEOPLASIA DETECTION IN BARRETT’S ESOPHAGUS

Wouter B. Nagengast  et al.

DOMAIN-SPECIFIC PRETRAINING OF DEEP LEARNING SYSTEMS IN GASTROINTESTINAL ENDOSCOPY IMPROVES PERFORMANCE OVER CURRENT STATE-OF-THE-ART PRETRAINING METHODS
DOMAIN-SPECIFIC PRETRAINING OF DEEP LEARNING SYSTEMS IN GASTROINTESTINAL ENDOSCOPY IMPROVES PERFORMANCE OVER CURRENT STATE-OF-THE-ART PRETRAINING METHODS

Wouter B. Nagengast  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK MUCOSAL ADENOCARCINOMA AND LOW- AND HIGH-RISK SUBMUCOSAL ADENOCARCINOMA ARISING IN BARRETT'S ESOPHAGUS, RESULTS OF 120 PATIENTS FROM THE DUTCH BARRETT EXPERT CENTER COHORT

Wouter B. Nagengast  et al.

RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?
RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?

Wouter B. Nagengast  et al.

FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Wouter B. Nagengast  et al.

COMPUTER AIDED DETECTION SYSTEM FOR REAL-TIME DETECTION OF BARRETT'S NEOPLASIA: A MULTI-CENTER PILOT AND FEASIBILITY STUDY
COMPUTER AIDED DETECTION SYSTEM FOR REAL-TIME DETECTION OF BARRETT'S NEOPLASIA: A MULTI-CENTER PILOT AND FEASIBILITY STUDY

Wouter B. Nagengast  et al.

POOR HEALING AND POOR SQUAMOUS REGENERATION AFTER RADIOFREQUENCY ABLATION THERAPY FOR EARLY BARRETT'S NEOPLASIA: INCIDENCE, RISK FACTORS, AND OUTCOMES
POOR HEALING AND POOR SQUAMOUS REGENERATION AFTER RADIOFREQUENCY ABLATION THERAPY FOR EARLY BARRETT'S NEOPLASIA: INCIDENCE, RISK FACTORS, AND OUTCOMES

Wouter B. Nagengast  et al.

OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANAEMIA: A MULTICENTRE RANDOMISED CONTROLLED TRIAL
OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANAEMIA: A MULTICENTRE RANDOMISED CONTROLLED TRIAL

Wouter B. Nagengast  et al.

THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES
THE NATURAL COURSE OF UNTREATED NEOPLASIA IN BARRETT’S ESOPHAGUS - A CASE-SERIES

Wouter B. Nagengast  et al.

VIDEO-BASED COMPUTER AIDED DETECTION SYSTEM IMPROVES BARRETT’S NEOPLASIA DETECTION OF GENERAL ENDOSCOPISTS IN A TWO-PHASE BENCHMARKING STUDY
VIDEO-BASED COMPUTER AIDED DETECTION SYSTEM IMPROVES BARRETT’S NEOPLASIA DETECTION OF GENERAL ENDOSCOPISTS IN A TWO-PHASE BENCHMARKING STUDY

Wouter B. Nagengast  et al.

MEDIUM-TERM ONCOLOGICAL OUTCOMES FOLLOWING ENDOSCOPIC FULL-THICKNESS RESECTION FOR T1 COLORECTAL CANCER: RESULTS FROM THE DUTCH PROSPECTIVE COLORECTAL EFTR REGISTRY
MEDIUM-TERM ONCOLOGICAL OUTCOMES FOLLOWING ENDOSCOPIC FULL-THICKNESS RESECTION FOR T1 COLORECTAL CANCER: RESULTS FROM THE DUTCH PROSPECTIVE COLORECTAL EFTR REGISTRY

Wouter B. Nagengast  et al.

QUANTITATIVE FLUORESCENCE MOLECULAR ENDOSCOPY USING CETUXIMAB-800CW TO EVALUATE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER; LESSONS LEARNED
QUANTITATIVE FLUORESCENCE MOLECULAR ENDOSCOPY USING CETUXIMAB-800CW TO EVALUATE RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER; LESSONS LEARNED

Wouter B. Nagengast  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR BARRETT'S RELATED NEOPLASIA IN THE NETHERLANDS: RESULTS OF A NATIONWIDE COHORT OF 130 CASES

Wouter B. Nagengast  et al.

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

Wouter B. Nagengast  et al.

Item 1 - 20 / 21
1
2